Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Application
Filed:
July 25, 2001
Publication date:
April 17, 2008
Applicant:
IDEC Pharmaceuticals Corporation
Inventors:
Darrell Anderson, Nabil hanna, Ronald Newman, Mitchell Reff, William Rastetter
Abstract: Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
Abstract: A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.
Type:
Grant
Filed:
April 1, 2002
Date of Patent:
January 11, 2005
Assignee:
Idec Pharmaceuticals Corporation
Inventors:
Mitchell R. Reff, Richard Spence Barnett, Karen Retta McLachlan
Abstract: Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed are methods for utilizing such polypeptides for identifying ligands, antagonists and agonists to said polypeptides. Finally, methods comprising the above-mentioned compositions are disclosed for the treatment, diagnosis, and/or prognosis of neoplastic disorders.
Type:
Application
Filed:
January 27, 2004
Publication date:
December 23, 2004
Applicant:
IDEC Pharmaceuticals Corporation
Inventors:
Karen McLachlan, Scott Glaser, Robert J. Peach, Tony Rowe
Abstract: The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
January 27, 2004
Assignee:
IDEC Pharmaceuticals Corporation
Inventors:
Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein ≦2×10−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer. A preferred target gene is Kv3.2.
Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
Type:
Application
Filed:
July 16, 2002
Publication date:
November 13, 2003
Applicant:
IDEC PHARMACEUTICALS CORPORATION
Inventors:
William H. Rastetter, Christine A. White
Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
Abstract: Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.
Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
Type:
Application
Filed:
June 17, 2002
Publication date:
September 18, 2003
Applicant:
IDEC PHARMACEUTICALS CORPORATION
Inventors:
Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland L. Newman
Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
Type:
Application
Filed:
June 17, 2002
Publication date:
September 11, 2003
Applicant:
IDEC PHARMACEUTICALS CORPORATION
Inventors:
Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
Abstract: Described herein is a novel expression system for producing multiple gene products of interest from a single polycistronic construct. In particular, the expression system contains a polycistronic vector capable of expressing functional antibodies in eukaryotic host cells, which vector contains at least the following elements operably linked in the 5′ to 3′ orientation: a promoter operable in a eukaryotic cell; a DNA sequence encoding at least the variable region of an antibody light chain; an internal ribosome entry site (IRES); and at least one DNA sequence encoding an antibody heavy chain. Also disclosed are mammalian cells containing the polycistronic expression vector, and a method of producing functional antibodies in mammalian cells transfected with the polycistronic expression vector.
Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Application
Filed:
September 11, 2002
Publication date:
August 7, 2003
Applicant:
IDEC PHARMACEUTICALS CORPORATION
Inventors:
Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Type:
Application
Filed:
July 25, 2001
Publication date:
May 22, 2003
Applicant:
IDEC Pharmaceuticals Corporation
Inventors:
Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
Type:
Application
Filed:
August 5, 2002
Publication date:
April 24, 2003
Applicant:
IDEC Pharmaceuticals Corporation
Inventors:
Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
Type:
Application
Filed:
July 10, 2002
Publication date:
April 3, 2003
Applicant:
IDEC Pharmaceuticals Corporation
Inventors:
Mitchell E. Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Marie Hardwick
Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
Type:
Application
Filed:
March 25, 2002
Publication date:
March 27, 2003
Applicant:
IDEC Pharmaceutical Corporation
Inventors:
Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.